Advanced search
Publication Cover
Journal of Asthma Volume 58, 2021 - Issue 4
Submit an article Journal homepage
6,259
Views
27
CrossRef citations to date
0
Altmetric
Therapeutics

Two-year integrated steroid-sparing analysis and safety of benralizumab for severe asthma

Arnaud Bourdina Department of Respiratory Diseases, Université de Montpellier, CHU Montpellier, PhyMedExp, INSERM, CNRS, Montpellier, FranceCorrespondence[email protected]
View further author information
, MD, PhD,
Dominick Shawb Division of Respiratory Medicine, University of Nottingham, Nottingham, UKView further author information
, MD,
Andrew Menzies-Gowc Department of Respiratory Medicine, Royal Brompton Hospital, London, UKView further author information
, MD, PhD,
J. Mark FitzGeraldd Centre for Heart and Lung Health, The Lung Centre Vancouver General Hospital, UBC Institute for Heart and Lung Health, Vancouver, CanadaView further author information
, MD,
Eugene R. Bleeckere Divisions of Pharmacogenomics and Genetics, Genomics and Precision Medicine, University of Arizona College of Medicine, Tucson, AZ, USAView further author information
, MD,
William W. Bussef Department of Medicine, Division of Allergy, Pulmonary and Critical Care Medicine, University of Wisconsin School of Medicine and Public Health, Madison, WI, USAView further author information
, MD,
Gary T. Fergusong Pulmonary Medicine, Internal Medicine, Critical Care Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USAView further author information
, MD,
Laura Brooksh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information
, MSc,
Peter Barkerh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information
, PhD,
Esther Garcia Gili Global Medical Affairs, AstraZeneca, Barcelona, SpainView further author information
, MD &
Ubaldo J. Martinh Research and Development, AstraZeneca, Gaithersburg, MD, USAView further author information
, MD show all
Pages 514-522 | Received 07 Nov 2019, Accepted 11 Dec 2019, Published online: 26 Dec 2019

References

  • Chen S, Golam S, Myers J, Bly C, Smolen H, Xu X. Systematic literature review of the clinical, humanistic, and economic burden associated with asthma uncontrolled by GINA Steps 4 or 5 treatment. Curr Med Res Opin. 2018;34(12):2075–2088. doi:10.1080/03007995.2018.1505352.
  • Menzies-Gow A, Canonica GW, Winders TA, Correia de Sousa J, Upham JW, Fink-Wagner AH. A charter to improve patient care in severe asthma. Adv Ther. 2018;35(10):1485–1496. doi:10.1007/s12325-018-0777-y.
  • Ramsahai JM, Wark PA. Appropriate use of oral corticosteroids for severe asthma. Med J Aust. 2018;209(S2):S18–S21.
  • Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term observational study. J Asthma Allergy. 2018;Volume 11:193–204. doi:10.2147/JAA.S176026.
  • Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, Reed JL, Woods R, Dall'acqua WW, Stephens GL, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353. doi:10.1016/j.jaci.2010.04.004.
  • Pham TH, Damera G, Newbold P, Ranade K. Reductions in eosinophil biomarkers by benralizumab in patients with asthma. Respir Med. 2016;111:21–29. doi:10.1016/j.rmed.2016.01.003.
  • Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, Sproule S, Gilmartin G, Aurivillius M, Werkström V, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2115–2127. doi:10.1016/S0140-6736(16)31324-1.
  • FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, Ferguson GT, Busse WW, Barker P, Sproule S, et al. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388(10056):2128–2141. doi:10.1016/S0140-6736(16)31322-8.
  • Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, Barker P, Sproule S, Ponnarambil S, Goldman M. ZONDA trial investigators. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501.
  • Busse WW, Bleecker ER, FitzGerald JM, Ferguson GT, Barker P, Sproule S, Olsson RF, Martin UJ, Goldman M, et al. BORA study investigators. Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial. Lancet Respir Med. 2019;7(1):46–59., doi:10.1016/S2213-2600(18)30406-5.
  • Waljee AK, Rogers MA, Lin P, Singal AG, Stein JD, Marks RM, Ayanian JZ, Nallamothu BK. Short term use of oral corticosteroids and related harms among adults in the United States: population based cohort study. BMJ. 2017;357:j1415. doi:10.1136/bmj.j1415.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.